Universal Ibogaine Profit Margin

The latest profit margin for IBOGF is -71.66% as of April 2025. That compares with -66.93% in the prior-year period — down 7.1% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Universal Ibogaine's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBOGF's profit margin moved from -66.93% to -71.66% — a 7.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Universal Ibogaine's valuation or profitability profile.

Against Healthcare companies, IBOGF currently prints -71.66% for profit margin, while the sector average sits near 10.58%. That is roughly 777.3% below the sector mean. Large gaps often invite a closer look at Universal Ibogaine's growth, margins, and balance sheet.

Profit Margin shows how effectively Universal Ibogaine converts resources into returns. At -71.66%, IBOGF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -66.93% in the prior-year period — down 7.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IBOGF's profit margin (-71.66%), review year-over-year change from -66.93%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.